Form 8-K Conatus Pharmaceuticals For: Dec 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
December 6, 2018 9:16 AM ESTH.C. Wainwright analyst Ed Arce lowered the price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to $14.00 (from $15.00) while maintaining a Buy rating.
Arce commented, "We fully expect CNAT shares to drop over 10% today as some investors will undoubtedly look no further at yesterday's release of the ENCORE-PH top-line results, than to see that the study missed its primary endpoint. Following this expected initial... More
